All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.
TRANSLATE
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View ALL content recommended for you
ASH 2022
24 Feb 2023
Revisit this:
🎥 #ASH22 | The ALL Hub spoke with @MRLitzow. We asked, Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult patients with B-ALL in MRD⁻ remission?
Watch the full video here 👉 https://t.co/2xMwtB2PGM. #ALLsm
🎥 #ASH22 | The ALL Hub spoke with @MRLitzow. We asked, Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult patients with B-ALL in MRD⁻ remission?
Watch the full video here 👉 https://t.co/2xMwtB2PGM. #ALLsm
21 Feb 2023
What trials are currently investigating menin-KMT2A inhibition for the treatment of ALL? To find out more about the novel therapies revumenib * ziftomenib, read our summary of the #ASH22 presentations by @GhayasIssa and Harry Erba 👉 https://t.co/TspBjqXjJc.
#leusm #leukemia
#leusm #leukemia
15 Feb 2023
Hot topics on the treatment of adult patients with Philadelphia-negative ALL were presented during #ASH22. Read more here 👉 https://t.co/ZrNzspfV73. #allsm #leusm
13 Feb 2023
Revisit this:
🎥 #ASH22 | The ALL Hub spoke with @NicholasShortMD. We asked, Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Watch the full video here 👉 https://t.co/ygybfEKEaM #ALLsm
🎥 #ASH22 | The ALL Hub spoke with @NicholasShortMD. We asked, Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Watch the full video here 👉 https://t.co/ygybfEKEaM #ALLsm
13 Feb 2023
RT @ALL_Hub_: 🎥 #ASH22 | The Lymphoma Hub spoke with @LoriMuffly, Stanford Medicine, Stanford, US. We asked about the geographical barriers…
9 Feb 2023
🎥 #ASH22 | The Lymphoma Hub spoke with @LoriMuffly, Stanford Medicine, Stanford, US. We asked about the geographical barriers to accessing specialty cancer care among adolescents and young adults with ALL?
Click here to see what was said 👉 https://t.co/B2xdOZSGrW. #lymsm
Click here to see what was said 👉 https://t.co/B2xdOZSGrW. #lymsm
6 Feb 2023
Novel treatment approaches in adult patients with newly diagnosed and R/R Ph+ ALL were presented during #ASH22. Read more here 👉 https://t.co/m28PhfjQVs. #leusm
23 Jan 2023
🎥 #ASH22 | The ALL Hub spoke with @MRLitzow. We asked, Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult patients with B-ALL in MRD⁻ remission? #ALLsm
Watch the full video here 👉 https://t.co/9gs2aVpdU5.
Watch the full video here 👉 https://t.co/9gs2aVpdU5.
19 Jan 2023
Results from the phase II GMALL-INITIAL1 trial of inotuzumab ozogamicin in older patients (>55 years) with de novo B-ALL were presented by Stelljes at #ASH22. Check out our summary here 👉 https://t.co/q0nbxR1F4l. #allsm #leusm
13 Jan 2023
🎥 #ASH22 | The ALL Hub spoke with @NicholasShortMD. We asked, Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL? #ALLsm
Watch the full video here 👉 https://t.co/Wr8cNYv8GN.
Watch the full video here 👉 https://t.co/Wr8cNYv8GN.
6 Jan 2023
🎥 #ASH22 | The ALL Hub spoke with @KSchmiegelow. We asked, How can you increase asparaginase adherence & manage hypersensitivity in adults with ALL? Watch the full video here 👉 https://t.co/RCB0C8nd6w. #ALLsmm
14 Dec 2022
We hope you enjoyed following our live updates and congress coverage from #ASH22!
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #leusm #allsm
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #leusm #allsm
13 Dec 2022
One of the abstracts that was mention in the best of #ASH22 session! Have a read below of our coverage: https://t.co/G3oWHD2Oyq
13 Dec 2022
RT @AML_Hub: CONGRESS | #ASH22
@profshanecrotty from @ljiresearch discusses SARS-CoV-2 and data gathered to access immunological memory pos…
@profshanecrotty from @ljiresearch discusses SARS-CoV-2 and data gathered to access immunological memory pos…
13 Dec 2022
CONGRESS | #ASH22
Drew Weissman, @WeissmanLab, discusses the development of RNA vaccinations for COVID-19 with the use of anti-CD4-targeted LNP and the use of cas9 or CPF1 gene editors. Summarizing that in vivo gene therapy is fiscally capable during the presidential symposium.
Drew Weissman, @WeissmanLab, discusses the development of RNA vaccinations for COVID-19 with the use of anti-CD4-targeted LNP and the use of cas9 or CPF1 gene editors. Summarizing that in vivo gene therapy is fiscally capable during the presidential symposium.
13 Dec 2022
CONGRESS | #ASH22 | Poster
Sjoerd Hermans, of @ErasmusMC presented data on the benefits and risks of Clofarabine from a multistate-modelling analysis of adult pts with ALL (HOVON 100 trial); It was found to be associated with an increased risk of cumulative toxicity
#leusm
Sjoerd Hermans, of @ErasmusMC presented data on the benefits and risks of Clofarabine from a multistate-modelling analysis of adult pts with ALL (HOVON 100 trial); It was found to be associated with an increased risk of cumulative toxicity
#leusm
13 Dec 2022
CONGRESS | #ASH22 | Poster
@NicholasShortMD, @MDAndersonNews shared the updated phase II results of InO added to hyper-CVAD + blinatumomab in pts with ND Ph-negative B-ALL, which proved highly effective and safe, with an estimated 1-year OS of 100% #allsm #leusm
@NicholasShortMD, @MDAndersonNews shared the updated phase II results of InO added to hyper-CVAD + blinatumomab in pts with ND Ph-negative B-ALL, which proved highly effective and safe, with an estimated 1-year OS of 100% #allsm #leusm
13 Dec 2022
CONGRESS|#ASH22 |Poster
Matthew Greenwood, @Sydney_Uni presented preliminary results on the use of blinatumomab in protocol I phase 2 of BFM-based protocol for AYAs with Ph-neg ALL(ALL09 study); higher rates of day 79 MRD negativity was observed when compared to ALL06 cohort
Matthew Greenwood, @Sydney_Uni presented preliminary results on the use of blinatumomab in protocol I phase 2 of BFM-based protocol for AYAs with Ph-neg ALL(ALL09 study); higher rates of day 79 MRD negativity was observed when compared to ALL06 cohort
13 Dec 2022
CONGRESS | #ASH22 | Poster
@manalipatelmd @standordmed discussed a health quality improvement program to address racial inequity & advance quality care for adults with #ALL. Access to care, effective SDM & clinical trial enrollment were found to be the main barriers #allsm #leusm
@manalipatelmd @standordmed discussed a health quality improvement program to address racial inequity & advance quality care for adults with #ALL. Access to care, effective SDM & clinical trial enrollment were found to be the main barriers #allsm #leusm
13 Dec 2022
CONGRESS | #ASH22 | Poster
@DrMarcosdelima of @OSUWexMed presents results from a registry-based observation study regarding veno-occlusive disease risk and other outcomes in patients with B-cell precursor #ALL who received inotuzumab ozogamicin & proceeded to HSCT. #allsm #leusm
@DrMarcosdelima of @OSUWexMed presents results from a registry-based observation study regarding veno-occlusive disease risk and other outcomes in patients with B-cell precursor #ALL who received inotuzumab ozogamicin & proceeded to HSCT. #allsm #leusm
13 Dec 2022
CONGRESS | #ASH22 | Poster
Ibrahim Aldoss, @cityofhope presented a retrospective study on outcomes of pts with R/R B-ALL treated with blinatumomab, inotuzumab, or CAR-T. All 3 therapies were shown to be highly effective with CR rates of over 60% and up to 90%.
#ALLsm
Ibrahim Aldoss, @cityofhope presented a retrospective study on outcomes of pts with R/R B-ALL treated with blinatumomab, inotuzumab, or CAR-T. All 3 therapies were shown to be highly effective with CR rates of over 60% and up to 90%.
#ALLsm
13 Dec 2022
CONGRESS | #ASH22 | Poster
Bijal D. Shah @MoffittNews presented updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of KTE-X19 in adult pts with R/R B-ALL. Results showed considerable benefits of KTE-X19 over SOC therapies #allsm #leusm
Bijal D. Shah @MoffittNews presented updated outcomes from the historical control study SCHOLAR-3 contextualizing ZUMA-3 results of KTE-X19 in adult pts with R/R B-ALL. Results showed considerable benefits of KTE-X19 over SOC therapies #allsm #leusm
13 Dec 2022
CONGRESS | #ASH22 | Poster
Luke Maese @huntsmancancer reported part B of phase II/III AALL1931 study of JZP458 in pts with ALL/LBL. JZP458 IV 25 mg/m2/48 hours was efficacious with NSAA levels ≥0.1 IU/mL in ≥90% of pts, safety was similar to other asparaginases #allsm #leusm
Luke Maese @huntsmancancer reported part B of phase II/III AALL1931 study of JZP458 in pts with ALL/LBL. JZP458 IV 25 mg/m2/48 hours was efficacious with NSAA levels ≥0.1 IU/mL in ≥90% of pts, safety was similar to other asparaginases #allsm #leusm
13 Dec 2022
CONGRESS | #ASH22 | Poster Ibrahim Aldoss @cityofhope talks on consolidation with alloHCT in adult pts with R/R ALL following response to memory-enriched CD19 CAR T-cells. N=58, positive outcomes including in pts receiving their 2nd alloHCT, transplant improved OS #allsm #leusm
13 Dec 2022
CONGRESS | #ASH22 | Poster @FedericoLussana @ Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII presented phase I/II study results of CART-cells engineered with sleeping beauty in pediatric pts with B-ALL relapsed post-HSCT. N=27, CR:76%, OS: 71% at 6 months. #allsm #leusm
13 Dec 2022
CONGRESS |#ASH22| Poster
@WNMacaron, @MDAndersonNews presented the phase II sub-study results of ponatinib + blinatumomab in pts with R/R Ph+ALL(n=14) or CML-LBP(n=6), which proved effective and safe in both cohorts. A high CMR rate of 79% was observed in R/R Ph+ ALL
#leusm
@WNMacaron, @MDAndersonNews presented the phase II sub-study results of ponatinib + blinatumomab in pts with R/R Ph+ALL(n=14) or CML-LBP(n=6), which proved effective and safe in both cohorts. A high CMR rate of 79% was observed in R/R Ph+ ALL
#leusm
13 Dec 2022
CONGRESS| #ASH22| Poster
Christina Egnell Gustafsson, Karolinska institutet described incidence of, and risk factors associated with HD-MTX-related toxicities in childhood ALL. After 1st course, severe toxicities were common and high MTX concentrations predicted nephrotoxicity
Christina Egnell Gustafsson, Karolinska institutet described incidence of, and risk factors associated with HD-MTX-related toxicities in childhood ALL. After 1st course, severe toxicities were common and high MTX concentrations predicted nephrotoxicity
12 Dec 2022
#ASH22| @LoriMuffly @Stanford discusses geographical barriers to assessing speciality cancer care among adolescents and young adults with ALL. She highlights limited geographical proximity to NCI cancer centres results in severe access issues #leukemia #leusm #medicalcongress
12 Dec 2022
#ASH22| Xing Wong @medisixtx discusses an off-the-shelf CAR-T therapy for T-ALL, not requiring gene editing. The study shows the feasibility of using 2 PEBLs for intracellular protein retention without compromising critical CAR-T functions #leukemia #leusm #medicalcongress
12 Dec 2022
#ASH22| Peihua Lu, Beijing Lu Daopei Institute of Hematology, presents analysis of 53 pts with T-ALL/TLBL treated with CD7-targeted CAR-T therapy. The new method was safe and highly effective with pts experiencing only mild CRS and neurotoxicity #leukemia #leusm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 David R. Freyer presents a comparison of OS in AYA pts with newly-diagnosed #ALL treated with pediatric-inspired (PIR) or non-pediatric inspired regimens. Those treated with a PIR showed significantly better OS
#leusm #medicalcongress #hematology
#leusm #medicalcongress #hematology
12 Dec 2022
CONGRESS| #ASH22 Sarah Tasian, of @ChildrensPhila discusses the clinical diagnostic approaches and the developing role of TKI’s for pts with Ph-like ALL, using case-based scenarios. She also highlighted current & planned clinical trials in this patient subset
#leusm #allsm
#leusm #allsm
12 Dec 2022
CONGRESS| #ASH22 @psaultier @aphm_actu discusses how cardiac and vascular risks are essential parameters for long-term surveillance of lower risk childhood acute #leukemia survivors. The results support prolonged follow-up in this patient group
#leusm #medicalcongress #hematology
#leusm #medicalcongress #hematology
12 Dec 2022
CONGRESS | #ASH22 @tpmiller12 @ATLPedsHemOnc addresses severe adverse events associated with concentrations of HDMTX in pediatric #ALL patients. Concentrations of HDMTX were modelled over time, revealing an association with AE development.
#leusm #medicalcongress #hematology
#leusm #medicalcongress #hematology
12 Dec 2022
CONGRESS | #ASH22 @AmanWadhwaMD @UAB_ICOS discusses poverty during maintenance and associated relapse risk in children with #ALL: COG-AALL03N1. Extreme household poverty is associated with increased relapse risk in children receiving maintenance therapy for ALL
#leusm #hematology
#leusm #hematology
12 Dec 2022
CONGRESS|#ASH22| Poster
Jordi Ribera, @CarrerasIJC presented preliminary data on the prognostic impact of IKZF1 deletions in adult pts with Ph-negative B-ALL, treated in the PETHEMA LAL19 trial. Results suggest IKZF1 deletions may be a marker of poor treatment response #leusm
Jordi Ribera, @CarrerasIJC presented preliminary data on the prognostic impact of IKZF1 deletions in adult pts with Ph-negative B-ALL, treated in the PETHEMA LAL19 trial. Results suggest IKZF1 deletions may be a marker of poor treatment response #leusm
12 Dec 2022
CONGRESS | #ASH22
Leland Metheny, @UHhospitals, presents phase I data of post-transplant low-dose maintenance inotuzumab ozogamicin in relapsed ALL (n = 18). 1-year post-HSCT OS = 94% & PFS = 89%. 1-year TRM = 56%. Most common G3/4 AE was thrombocytopenia. MTD = 0.6mg/m2.
#leusm
Leland Metheny, @UHhospitals, presents phase I data of post-transplant low-dose maintenance inotuzumab ozogamicin in relapsed ALL (n = 18). 1-year post-HSCT OS = 94% & PFS = 89%. 1-year TRM = 56%. Most common G3/4 AE was thrombocytopenia. MTD = 0.6mg/m2.
#leusm
12 Dec 2022
CONGRESS|#ASH22
@emilyliangmd, of @UW presents results evaluating the prognostic value of ultra-sensitive NGS-based MRD in a large cohort of adults with ALL undergoing HCT. Very low levels of detected MRD, both pre-and post HCT, was associated with increased risk of relapses
@emilyliangmd, of @UW presents results evaluating the prognostic value of ultra-sensitive NGS-based MRD in a large cohort of adults with ALL undergoing HCT. Very low levels of detected MRD, both pre-and post HCT, was associated with increased risk of relapses
12 Dec 2022
CONGRESS |#ASH22 Shawn Lee, @StJudeResearch highlights results from the drug sensitivity analysis of pediatric ALL subtypes, and its effect on in vivo treatment responses. Pharmacotypes varied widely across subtypes and strongly impacted treatment response and survival outcomes
12 Dec 2022
CONGRESS| #ASH22
@PolonenPetri, @StJudeResearch presents data on the oncogenic drivers and genetic predictors of disease outcomes identified amongst T-ALL subtypes in childhood pts. The study involved the use of an integrated genomic analysis. #allsm #leusm
@PolonenPetri, @StJudeResearch presents data on the oncogenic drivers and genetic predictors of disease outcomes identified amongst T-ALL subtypes in childhood pts. The study involved the use of an integrated genomic analysis. #allsm #leusm
12 Dec 2022
CONGRESS|ASH22|Poster
@jayastuMD,@MDAndersonNews discusses predictors of VOD of the liver for pts treated with InO containing regimen in B-cell ALL. Fractionation of InO doses, avoiding concurrent azole antifungals & use of UDCA prophylaxis & peri-SCT period might alleviate risks
@jayastuMD,@MDAndersonNews discusses predictors of VOD of the liver for pts treated with InO containing regimen in B-cell ALL. Fractionation of InO doses, avoiding concurrent azole antifungals & use of UDCA prophylaxis & peri-SCT period might alleviate risks
12 Dec 2022
CONGRESS|#ASH22|Poster
@AngusHodder,delivered results on a treatment strategy of reduced intensity reinduction, followed by consolidative blinatumomab in children & young adults with relapsed B-ALL, leading to excellent MRD clearance with reduced toxicity, and allowed timely HSCT
@AngusHodder,delivered results on a treatment strategy of reduced intensity reinduction, followed by consolidative blinatumomab in children & young adults with relapsed B-ALL, leading to excellent MRD clearance with reduced toxicity, and allowed timely HSCT
12 Dec 2022
CONGRESS | #ASH22 | Poster | @JosephineAnneMD @UHN reported distinct clinical/biological characteristics & outcomes of T-ALL post #MultipleMyeloma vs other cancers. No BCR::ABL1 translocation or MLL rearrangement, high CR rate, longer median OS with/without alloSCT #allsm #leusm
12 Dec 2022
CONGRESS | #ASH22 | Poster
Sabina Chiaretti presented results from the GIMEMA LAL2317 study, which aimed to refine risk relapse categories of Ph-like #ALL, based on genomic features. Pts with Ph-like ALL often relapse after blinatumomab treatment.
#ALLsm #medicalcongress
Sabina Chiaretti presented results from the GIMEMA LAL2317 study, which aimed to refine risk relapse categories of Ph-like #ALL, based on genomic features. Pts with Ph-like ALL often relapse after blinatumomab treatment.
#ALLsm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 | Poster
Anthony Stein discussed the study design of the ongoing, first-in-human study to evaluate use of SAR443579 for pts with R/R AML, B-ALL and HR-MDS. The study will enrol ~82 pts over the dose escalation and expansion phases.
#ALLsm #medicalcongress
Anthony Stein discussed the study design of the ongoing, first-in-human study to evaluate use of SAR443579 for pts with R/R AML, B-ALL and HR-MDS. The study will enrol ~82 pts over the dose escalation and expansion phases.
#ALLsm #medicalcongress
12 Dec 2022
CONGRESS|#ASH22|Poster
Daniel Nguyen from The University of Texas Health Science Center presented the phase II study results on the sequential combination use of mini-hyper-CVD, blinatumomab, and ponatinib in pts with Ph+ ALL, which proved highly effective and was well-tolerated
Daniel Nguyen from The University of Texas Health Science Center presented the phase II study results on the sequential combination use of mini-hyper-CVD, blinatumomab, and ponatinib in pts with Ph+ ALL, which proved highly effective and was well-tolerated
11 Dec 2022
CONGRESS|#ASH22|Poster
Sarah Tasian, of @ChildrensPhila reported the biological characteristics and early treatment responses amongst pts with non-CRLF2-rearranged Ph-like ALL, in the phase II study of ruxolitinib + chemotherapy
#leusm #ALLsm #medicalcongress
Sarah Tasian, of @ChildrensPhila reported the biological characteristics and early treatment responses amongst pts with non-CRLF2-rearranged Ph-like ALL, in the phase II study of ruxolitinib + chemotherapy
#leusm #ALLsm #medicalcongress
11 Dec 2022
CONGRESS |#ASH22| Poster
Anna Østergaard, of @Oncodeinstitute presented results on the prognostic impact of IKZF1 deletions in childhood pts with ETV6::RUNX1 and High Hyperdiploid ALL, analyzed across 16 trials
#leukemia #medicalcongress
Anna Østergaard, of @Oncodeinstitute presented results on the prognostic impact of IKZF1 deletions in childhood pts with ETV6::RUNX1 and High Hyperdiploid ALL, analyzed across 16 trials
#leukemia #medicalcongress
11 Dec 2022
CONGRESS | #ASH22 | Poster
Giovanni Marconi presented a poster about use of inotuzumab ozogamicin in MRD+ pts with #ALL, without prior HSCT. The majority of both Ph+ and Ph- pts achieved MRD reduction or negativity. Median OS was not reached.
#medicalcongress #allsm
Giovanni Marconi presented a poster about use of inotuzumab ozogamicin in MRD+ pts with #ALL, without prior HSCT. The majority of both Ph+ and Ph- pts achieved MRD reduction or negativity. Median OS was not reached.
#medicalcongress #allsm
11 Dec 2022
CONGRESS| #ASH22| Poster
Patrice Nasnas, @MDAndersonNews presented the 6-yr follow-up results on the frontline combination of hyper-CVAD + ponatinib in pts with Ph+ ALL, which demonstrated high efficacy (CMR,87%; 6-yr EFS,65%; 6yr OS,75%) and safety #allsm #medicalcongress
Patrice Nasnas, @MDAndersonNews presented the 6-yr follow-up results on the frontline combination of hyper-CVAD + ponatinib in pts with Ph+ ALL, which demonstrated high efficacy (CMR,87%; 6-yr EFS,65%; 6yr OS,75%) and safety #allsm #medicalcongress
11 Dec 2022
CONGRESS|#ASH22|Poster
Peihua Lu, Lu Daopei Hospital presented the phase I results of RD13-01, a novel CD7-targeted UCAR-T, in R/R T-ALL/T-LBL, which showed safety and dose-dependent effectiveness. Longer-term observation and a larger cohort are needed for further evaluations.
Peihua Lu, Lu Daopei Hospital presented the phase I results of RD13-01, a novel CD7-targeted UCAR-T, in R/R T-ALL/T-LBL, which showed safety and dose-dependent effectiveness. Longer-term observation and a larger cohort are needed for further evaluations.
11 Dec 2022
CONGRESS| #ASH22
Andrew Hantel, @DanaFarber presented analyzed data from 2014-2018 on the sociodemographic differences in the access and initial treatment of pts with acute #leukemia across the DFCI catchment areas, revealing targetable groups for improving equitable care
Andrew Hantel, @DanaFarber presented analyzed data from 2014-2018 on the sociodemographic differences in the access and initial treatment of pts with acute #leukemia across the DFCI catchment areas, revealing targetable groups for improving equitable care
10 Dec 2022
CONGRESS #ASH22|
Elias Jabbour, @MDAndersonNews shares the US-based phase 1B study results of olverembatinib in pts with TKI-refractory CML and Ph+ ALL which showed efficacy and safety up to 50mg QOD; strong efficacy seen in pts with CML who were resistant to ponatinib #allsm
Elias Jabbour, @MDAndersonNews shares the US-based phase 1B study results of olverembatinib in pts with TKI-refractory CML and Ph+ ALL which showed efficacy and safety up to 50mg QOD; strong efficacy seen in pts with CML who were resistant to ponatinib #allsm
10 Dec 2022
CONGRESS| #ASH22
@NitinJainMD, @MDAndersonNews shares safety and preliminary efficacy data from the ongoing phase 1 study of ADCT-602, a CD22 targeting ADC bound to PBD toxin, in adult (≥18 years) pts with R/R B-ALL; well-tolerated overall (one DLT at dose 50µg/kg) #leusm
@NitinJainMD, @MDAndersonNews shares safety and preliminary efficacy data from the ongoing phase 1 study of ADCT-602, a CD22 targeting ADC bound to PBD toxin, in adult (≥18 years) pts with R/R B-ALL; well-tolerated overall (one DLT at dose 50µg/kg) #leusm
10 Dec 2022
CONGRESS| #ASH22
@NicholasShortMD, @MDAndersonNews presents the phase II sub-study results of ponatinib + blinatumomab in pts with ND Ph+ ALL(n=40). It was well tolerated with high rates of CMR(87%) and NGS MRD negativity(88%), and estimated 2-year OS of 95% #allsm #leusm
@NicholasShortMD, @MDAndersonNews presents the phase II sub-study results of ponatinib + blinatumomab in pts with ND Ph+ ALL(n=40). It was well tolerated with high rates of CMR(87%) and NGS MRD negativity(88%), and estimated 2-year OS of 95% #allsm #leusm
10 Dec 2022
CONGRESS|#ASH22
Dr Matthias Stelljes, @WWU_Muenster reports the GMALL-Initial1 trial results on inotuzumab ozogamicin induction, followed by standard chemo in pts aged >55 yrs with ND Ph neg BCP-ALL. Primary endpoint was met; high remission rates and low toxicities observed.
Dr Matthias Stelljes, @WWU_Muenster reports the GMALL-Initial1 trial results on inotuzumab ozogamicin induction, followed by standard chemo in pts aged >55 yrs with ND Ph neg BCP-ALL. Primary endpoint was met; high remission rates and low toxicities observed.
10 Dec 2022
CONGRESS #ASH22|
@NicBoissel @HopSaintLouis presents a comparison analysis of two high-risk, Ph neg BCP-ALL adult cohorts within GRAALL-2014/B trial treated w/wo blina during consolidation. Blina was associated with a significantly lower CIR (52% reduction) and prolonged DFS
@NicBoissel @HopSaintLouis presents a comparison analysis of two high-risk, Ph neg BCP-ALL adult cohorts within GRAALL-2014/B trial treated w/wo blina during consolidation. Blina was associated with a significantly lower CIR (52% reduction) and prolonged DFS
10 Dec 2022
CONGRESS| #ASH22 Dr. Nicola Goekbuget, @goetheuni reported outcomes of 841 older (>55years) pts with Ph negative ALL treated using pediatric-based, age-adapted GMALL protocols. #allsm #leusm #medicalcongress
10 Dec 2022
CONGRESS| #ASH22 @Wang_Rwang, @StJudeResearch discusses the prognostic effects of IKZF1 alterations amongst 688 pediatric pts with B-ALL, treated in the Total XV and XVI studies.
Pts with IKZF1plus had the poorest prognostic outcomes #leusm
Pts with IKZF1plus had the poorest prognostic outcomes #leusm
10 Dec 2022
CONGRESS| #ASH22 Nicola Goekbuget, @goetheuni reported the updated results of the risk-adapted, MRD-stratified GMALL Trial 08/2013 in 281 adult pts with T- ALL/LBL. OS=78% for total cohort. Thymic T-ALL was shown to be a low-risk subgroup. #allsm #leusm
10 Dec 2022
CONGRESS #ASH22 | @NicBoissel, @HopSaintLouis delivers results from the GrAALL-2014 trial in adult pts with Ph-ALL which revealed that age-adapted chemotherapy intensity and MRD-driven indication for HSCT significantly reduced TRM, improved OS, and well-tolerated overall #leusm
8 Dec 2022
What are your top picks?
Discover our list of top abstracts for the 64th @ASH_Hematology Annual Meeting & Exposition!
The abstracts, selected by our steering committee, provide the latest updates in #acutelymphomblasticleukaemia. #ASH22
Learn more: https://t.co/91fcrHa4nm.
Discover our list of top abstracts for the 64th @ASH_Hematology Annual Meeting & Exposition!
The abstracts, selected by our steering committee, provide the latest updates in #acutelymphomblasticleukaemia. #ASH22
Learn more: https://t.co/91fcrHa4nm.
6 Dec 2022
Get ready for #ASH22 with us!
The list of top abstracts selected by our steering committee for the @ASH_hematology Annual Meeting is now available on the @ALL_Hub_!
📌Find out more: https://t.co/91fcrHa4nm.
#lymsm #allsm #medicalabstracts #medicaljournal #cancerresearch
The list of top abstracts selected by our steering committee for the @ASH_hematology Annual Meeting is now available on the @ALL_Hub_!
📌Find out more: https://t.co/91fcrHa4nm.
#lymsm #allsm #medicalabstracts #medicaljournal #cancerresearch
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content